Celia Eckert
Known title: VP, GENERAL COUNSELCIK: 0001787397
Associated companies
Transaction History
| XNCR | ▼ Sell | Open Market | 1,767 | $19K | 3/6/2026 | View on chart |
| XNCR | ▼ Sell | Open Market | 3,244 | $36K | 3/5/2026 | View on chart |
| XNCR | ▼ Sell | Open Market | 1,492 | $18K | 3/3/2026 | View on chart |
| XNCR | ▲ Buy | Grant | 18,680 | $0 | 3/2/2026 | View on chart |
| XNCR | ▼ Sell | Open Market | 5,740 | $78K | 3/10/2025 | View on chart |
| XNCR | ▲ Buy | Grant | 21,949 | $0 | 3/4/2025 | View on chart |
| XNCR | ▼ Sell | Open Market | 850 | $20K | 3/11/2024 | View on chart |
| XNCR | ▲ Buy | Grant | 13,089 | $0 | 3/5/2024 | View on chart |
| XNCR | ▼ Sell | Open Market | 3,892 | $91K | 3/5/2024 | View on chart |
| XNCR | ▼ Sell | Open Market | 711 | $21K | 3/9/2023 | View on chart |
| XNCR | ▼ Sell | Open Market | 2,462 | $77K | 3/6/2023 | View on chart |
| XNCR | ▼ Sell | Open Market | 427 | $13K | 3/3/2023 | View on chart |
| XNCR | ▲ Buy | Grant | 10,504 | $0 | 3/2/2023 | View on chart |
| XNCR | ▼ Sell | Open Market | 789 | $23K | 3/9/2022 | View on chart |
| XNCR | ▼ Sell | Open Market | 451 | $13K | 3/3/2022 | View on chart |
| XNCR | ▲ Buy | Grant | 19,904 | $0 | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
XNCR: Improved Funding for Obexelimab
Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.
XNCR: Improved Funding for Obexelimab. Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.